EXPRESSION OF GLYCOGEN SYNTHASE KINASE 3 BETA IN PATIENT OF PSORIASIS

Abdellatif, Mona El Sayed; Mahmoud, Lamis Ahmed; Rashed, Laila Ahmed; El-Rifaie, Abd-El Aziz

doi:10.21608/ejmr.2021.93612.1122

EXPRESSION OF GLYCOGEN SYNTHASE KINASE 3 BETA IN PATIENT OF PSORIASIS

Document Type : Original Article

Authors

¹ Dermatology and Venereology department, Faculty of Medicine, Beni-Suef University, Egypt

² Dermatology and Venereology department, Beni-Suef, Egypt

³ Biochemistry department, Faculty of Medicine, Cairo University, Egypt

10.21608/ejmr.2021.93612.1122

Abstract

The objective of the present investigation was to identify a correlation between GSK3β and the pathogenesis of psoriasis using PCR. A Case-Control research was undertaken from February 2019 to February 2020 at the Dermatology outpatient clinic of Beni-Suef University Hospital. This research included 30 patients with persistent plaque psoriasis and 30 age- and sex-matched healthy controls. Skin biopsies were obtained from all participants in the research (psoriasis sufferers and healthy controls) to examine the expression of GSK-3β. The expression of GSK-3β was markedly elevated in psoriasis skin lesions compared to healthy control skin (5.61 vs. 1.03; p-value <0.001). The expression of GSK3β was marginally elevated in male psoriasis patients relative to females, albeit this difference was not statistically significant (p-value = 0.674).There were non-statistically significant association of (GSK-3β) expression with disease onset, disease course and family history. Patients’ age was moderately negative correlated with (GSK-3β) expression; (r= -0.471, p= 0.009). The PASI score was strongly positive correlated with (GSK-3β) expression (r= 0.776, p<0.001). There may be roles of up-regulated (GSK-3β) in lesional skin of psoriasis patients as compared with healthy controls. Nonetheless, an additional gain-of-function or loss-of-function experiment may be beneficial to clarify the involvement of GSK-3β in psoriatic skin lesions

Keywords

Main Subjects

Internal medicine ·

References

1. Lee J, Song K, Hiebert P, Werner S, Kim TG, Kim YS. Tussilagonone Ameliorates Psoriatic Features in Keratinocytes and Imiquimod-Induced Psoriasis-Like Lesions in Mice via NRF2 Activation. J Invest Dermatol. 2020 Jun;140(6):1223-1232.e4. doi: 10.1016/j.jid.2019.12.008. Epub 2019 Dec 23. PMID: 31877316.
2. Rendon A, Schäkel K. Psoriasis Pathogenesis and Treatment. Int J Mol Sci. 2019 Mar 23;20(6):1475. doi: 10.3390/ijms20061475. PMID: 30909615; PMCID: PMC6471628.
3. Pandey MK, DeGrado TR. Glycogen Synthase Kinase-3 (GSK-3)-Targeted Therapy and Imaging. Theranostics. 2016 Feb 17;6(4):571-93. doi: 10.7150/thno.14334. PMID: 26941849; PMCID: PMC4775866.
4. Hoffmeister L, Diekmann M, Brand K, Huber R. GSK3: A Kinase Balancing Promotion and Resolution of Inflammation. Cells. 2020 Mar 28;9(4):820. doi: 10.3390/cells9040820. PMID: 32231133; PMCID: PMC7226814.
5. Cortés-Vieyra R, Silva-García O, Gómez-García A, Gutiérrez-Castellanos S, Álvarez-Aguilar C, Baizabal-Aguirre VM. Glycogen Synthase Kinase 3β Modulates the Inflammatory Response Activated by Bacteria, Viruses, and Parasites. Front Immunol. 2021 May 4;12:675751. doi: 10.3389/fimmu.2021.675751. PMID: 34017345; PMCID: PMC8129516.
6. Lauretti E, Dincer O, Praticò D. Glycogen synthase kinase-3 signaling in Alzheimer's disease. Biochim Biophys Acta Mol Cell Res. 2020 May;1867(5):118664. doi: 10.1016/j.bbamcr.2020.118664. Epub 2020 Jan 30. PMID: 32006534; PMCID: PMC7047718.
7. Peng H, Wang HB, Wang L, Zhou B, Li XY, Tan J. Gsk3β aggravates the depression symptoms in chronic stress mouse model. J Integr Neurosci. 2018;17(2):169-175. doi: 10.31083/JIN-170050. PMID: 29036833.
8. Muneer A. Wnt and GSK3 Signaling Pathways in Bipolar Disorder: Clinical and Therapeutic Implications. Clin Psychopharmacol Neurosci. 2017 May 31;15(2):100-114. doi: 10.9758/cpn.2017.15.2.100. PMID: 28449557; PMCID: PMC5426498.
9. Xin Y, Yuan Q, Liu C, Zhang C, Yuan D. MiR-155/GSK-3β mediates anti-inflammatory effect of Chikusetsusaponin IVa by inhibiting NF-κB signaling pathway in LPS-induced RAW264.7 cell. Sci Rep. 2020 Oct 27;10(1):18303. doi: 10.1038/s41598-020-75358-1. PMID: 33110183; PMCID: PMC7591521.
10. Lohning A, Kidachi Y, Kamiie K, Sasaki K, Ryoyama K, Yamaguchi H. 6-(methylsulfinyl)hexyl isothiocyanate (6-MITC) from Wasabia japonica alleviates inflammatory bowel disease (IBD) by potential inhibition of glycogen synthase kinase 3 beta (GSK-3β). Eur J Med Chem. 2021 Apr 15;216:113250. doi: 10.1016/j.ejmech.2021.113250. Epub 2021 Feb 13. PMID: 33691258.
11. Cortés-Vieyra R, Silva-García O, Gómez-García A, Gutiérrez-Castellanos S, Álvarez-Aguilar C, Baizabal-Aguirre VM. Glycogen Synthase Kinase 3β Modulates the Inflammatory Response Activated by Bacteria, Viruses, and Parasites. Front Immunol. 2021 May 4;12:675751. doi: 10.3389/fimmu.2021.675751. PMID: 34017345; PMCID: PMC8129516.
12. Roca C, Campillo NE. Glycogen synthase kinase 3 (GSK-3) inhibitors: a patent update (2016-2019). Expert Opin Ther Pat. 2020 Nov;30(11):863-872. doi: 10.1080/13543776.2020.1815706. Epub 2020 Sep 14. PMID: 32841101.
13. Lee EB, Wu KK, Lee MP, Bhutani T, Wu JJ. Psoriasis risk factors and triggers. Cutis. 2018 Nov;102(5S):18-20. PMID: 30566552.
14. Yu X, Yan N, Li Z, Hua Y, Chen W. FGF19 sustains the high proliferative ability of keratinocytes in psoriasis through the regulation of Wnt/GSK-3β/β-catenin signalling via FGFR4. Clin Exp Pharmacol Physiol. 2019 Aug;46(8):761-769. doi: 10.1111/1440-1681.13103. Epub 2019 Jun 3. PMID: 31074061.
15. Rendon A, Schäkel K. Psoriasis Pathogenesis and Treatment. Int J Mol Sci. 2019 Mar 23;20(6):1475. doi: 10.3390/ijms20061475. PMID: 30909615; PMCID: PMC6471628.
16. Glibo M, Serman A, Karin-Kujundzic V, Bekavac Vlatkovic I, Miskovic B, Vranic S, Serman L. The role of glycogen synthase kinase 3 (GSK3) in cancer with emphasis on ovarian cancer development and progression: A comprehensive review. Bosn J Basic Med Sci. 2021 Feb 1;21(1):5-18. doi: 10.17305/bjbms.2020.5036. PMID: 32767962; PMCID: PMC7861620.
17. Kassi K, Djeha D, Gbery IP, Kouame K, Sangaré A. Psoriasis in elderly patients in the Côte d'Ivoire: socio-demographic, clinical, and therapeutic aspects, and follow-up. Int J Dermatol. 2016 Feb;55(2):e83-6. doi: 10.1111/ijd.13138. Epub 2015 Oct 31. PMID: 26517980.
18. Maul JT, Navarini AA, Sommer R, Anzengruber F, Sorbe C, Mrowietz U, Drach M, Blome C, Boehncke WH, Thaci D, Reich K, von Kiedrowski R, Körber A, Yawalkar N, Mainetti C, Laffitte E, Streit M, Rustenbach S, Conrad C, Borradori L, Gilliet M, Cozzio A, Itin P, Häusermann P, French LE, Radtke MA, Augustin M. Gender and age significantly determine patient needs and treatment goals in psoriasis - a lesson for practice. J Eur Acad Dermatol Venereol. 2019 Apr;33(4):700-708. doi: 10.1111/jdv.15324. Epub 2019 Jan 15. PMID: 30388318.
19. Kundakci N, Türsen U, Babiker MO, Gürgey E. The evaluation of the sociodemographic and clinical features of Turkish psoriasis patients. Int J Dermatol. 2002 Apr;41(4):220-4. doi: 10.1046/j.1365-4362.2002.01462.x. PMID: 12031031.
20. Solmaz D, Bakirci S, Kimyon G, Gunal EK, Dogru A, Bayindir O, Dalkilic E, Ozisler C, Can M, Akar S, Cetin GY, Yavuz S, Kilic L, Tarhan EF, Kucuksahin O, Omma A, Gonullu E, Yildiz F, Ersozlu ED, Cinar M, Al-Onazi A, Erden A, Tufan MA, Yilmaz S, Pehlevan S, Kalyoncu U, Aydin SZ. Impact of Having Family History of Psoriasis or Psoriatic Arthritis on Psoriatic Disease. Arthritis Care Res (Hoboken). 2020 Jan;72(1):63-68. doi: 10.1002/acr.23836. PMID: 30680951.
21. El-Komy, M. H. M., Mashaly, H., Sayed, K. S., Hafez, V., El-Mesidy, M. S., Said, E. R., ... & Eid, R. O. Clinical and epidemiologic features of psoriasis patients in an Egyptian medical center. JAAD International. JAAD International, 2020, Pages 81-90, ISSN 2666-3287, doi: 10.1016/j.jdin.2020.06.002.
22. Aune D, Snekvik I, Schlesinger S, Norat T, Riboli E, Vatten LJ. Body mass index, abdominal fatness, weight gain and the risk of psoriasis: a systematic review and dose-response meta-analysis of prospective studies. Eur J Epidemiol. 2018 Dec;33(12):1163-1178. doi: 10.1007/s10654-018-0366-z. Epub 2018 Apr 21. PMID: 29680995; PMCID: PMC6290660.
23. Hoke GD, Ramos C, Hoke NN, Crossland MC, Shawler LG, Boykin JV. Atypical Diabetic Foot Ulcer Keratinocyte Protein Signaling Correlates with Impaired Wound Healing. J Diabetes Res. 2016;2016:1586927. doi: 10.1155/2016/1586927. Epub 2016 Oct 20. PMID: 27840833; PMCID: PMC5093264.
24. He R, Du S, Lei T, Xie X, Wang Y. Glycogen synthase kinase 3β in tumorigenesis and oncotherapy (Review). Oncol Rep. 2020 Dec;44(6):2373-2385. doi: 10.3892/or.2020.7817. Epub 2020 Oct 20. PMID: 33125126.
25. Lauretti E, Dincer O, Praticò D. Glycogen synthase kinase-3 signaling in Alzheimer's disease. Biochim Biophys Acta Mol Cell Res. 2020 May;1867(5):118664. doi: 10.1016/j.bbamcr.2020.118664. Epub 2020 Jan 30. PMID: 32006534; PMCID: PMC7047718.
26. Oshima, N., Ishihara, S., Fukuba, N., Mishima, Y., Kawashima, K., Ishimura, N., ... & Kinoshita, Y. Epidermal differentiation complex protein involucrin is down-regulated in eosinophilic esophagitis. Esophagus, 14(2), 171-177.‏ DOI 10.1007/s10388-016-0568-y. PMCID: PMC7610307.
27. Chen JQ, Man XY, Li W, Zhou J, Landeck L, Cai SQ, Zheng M. Regulation of involucrin in psoriatic epidermal keratinocytes: the roles of ERK1/2 and GSK-3β. Cell Biochem Biophys. 2013 Jul;66(3):523-8. doi: 10.1007/s12013-012-9499-y. PMID: 23283814.